preprint · bioRxiv (Cold Spring Harbor Laboratory)
Hookworm infection affects hundreds of millions of people worldwide, but no approved vaccine exists. An integrated computational and immunoinformatics assessment evaluated three clinically tested Necator americanus vaccine candidates: Na-APR-1, Na-GST-1, and Na-ASP-2. The computational models accurately mirrored past clinical outcomes by identifying Na-ASP-2 as allergenic and toxigenic, aligning with its known clinical failure. In contrast, Na-APR-1 demonstrated a favourable safety profile, the broadest selection of immune epitopes, strong binding to the immune receptor TLR4, and robust simulated cellular and antibody responses. Na-GST-1 displayed inconsistent allergenicity predictions and weaker simulated immune responses despite strong receptor binding. All three proteins showed broad projected coverage across global populations in endemic areas. Overall, the computational evaluations support prioritising Na-APR-1 for further clinical development while demonstrating how predictive screening can guide safer hookworm vaccine candidate selection.
Hookworm disease places a massive health burden on nearly half a billion people, yet safe vaccines remain unavailable. Clinical trials are expensive and can fail due to unexpected allergic reactions. Demonstrating that computer-driven screening accurately detects known safety failures and highlights viable candidates helps researchers identify safer, more effective antigens before entering costly human trials, accelerating the path towards effective hookworm immunisation.
This research aids vaccine developers and biopharmaceutical organisations by identifying Na-APR-1 as a prioritised candidate for continued clinical trials. It also offers an immunoinformatics screening pipeline to de-risk candidate selection prior to expensive wet-lab testing. Because the study is based on retrospective computational modelling and simulated immune dynamics, physical laboratory validation and clinical trials remain necessary before any resulting vaccine formulation can reach the market.
AI-generated from the published abstract. Always read the original work before citing.
Hookworm disease, primarily caused by Necator americanus, affects about 472 million people worldwide and contributes substantially to global disease burden, yet no approved vaccine is currently available. The clinical failure of Na-ASP-2 protein due to IgE-mediated hypersensitivity highlights the need for safe, immunogenic hookworm vaccines and emphasizes the importance of rigorous pre-clinical safety screening. Using an integrated immunoinformatics approach, this work retrospectively evaluated the safety and immunogenicity of three clinical hookworm protein vaccine candidates: Na-APR-1, Na-GST-1, and Na-ASP-2. Toxigenicity and allergenicity predictions correctly identified Na-ASP-2 as toxigenic and allergenic, consistent with its documented clinical failure, while Na-APR-1 exhibited a favourable safety profile; Na-GST-1 showed inconsistent allergenicity signals warranting experimental validation. Comprehensive epitope prediction identified abundant CTL, HTL, B-cell, and cytokine-inducing epitopes across all candidates, with Na-APR-1 demonstrating the broadest epitope repertoire. HLA population coverage analysis indicated broad global applicability across endemic regions. Molecular docking with TLR4 revealed that all antigens interact with the receptor with binding energies more favourable than the positive control agonist, with Na-GST-1 and Na-APR-1 displaying the strongest predicted affinities. Normal mode analyses predicted stable antigen-TLR4 complex dynamics across all candidates. Immune simulations predicted robust, memory-driven humoral and cellular responses for Na-APR-1 and Na-ASP-2, while Na-GST-1 showed markedly attenuated simulated immunogenicity despite favourable structural and receptor-binding characteristics. These findings support continued clinical development of Na-APR-1, highlight unresolved immunogenic discordances for Na-GST-1 requiring experimental verification, and collectively provide a validated computational framework for advancing rational hookworm vaccine design.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.64898/2026.09.02.748823
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
